Dr. Tobias Speck, VP of Product Development

Two sides of the same coin: Measles-vectored drugs for cancer immunotherapy and vaccines

The CanVirex platform deploys the oncolytic properties of recombinant measles vectors for innovative cancer treatments. In addition it has now provided a novel COVID-19 vaccine candidate that is approaching clinical trials. Produced by CanVirex in cooperation with: CanVirex was founded in 2017, based on the research of medical oncologist Guy Ungerechts from the Heidelberg University …

Two sides of the same coin: Measles-vectored drugs for cancer immunotherapy and vaccines Read More »